Optimal Therapy for Adult Patients with Acute Myeloid Leukemia in First Complete Remission

Overview

Journal Curr Treat Options Oncol

Specialty Oncology

Date 2014 May 6

PMID 24792016

Citations 3

Authors

Peter H Wiernik

Affiliations

Soon will be listed here.

Abstract

Although it is absolutely clear that postremission therapy is currently necessary to obtain disease-free long-term survivorship for patients with acute myeloid leukemia (AML) in first complete remission (CR), it is not entirely clear what form that treatment should take. High-dose cytarabine is clearly effective and there definitely is a dose-response relationship for cytarabine and remission duration. High-dose cytarabine is effective for younger patients but not elderly patients. It is effective for patients with favorable cytogenetics but it is not clear whether it is effective for patients with intermediate or unfavorable cytogenetics. Furthermore, it is not clear what the most effective and least toxic dose and schedule of high-dose cytarabine is.

Citing Articles

Comprehensive analysis of clinical prognostic features and tumor microenvironment landscape of CD11bCD64 patients with acute myeloid leukemia.

Wang Q, Zhang N, Liu L, Ma L, Tan Y, Liu X Cell Oncol (Dordr). 2023; 46(5):1253-1268.

PMID: 37071330 DOI: 10.1007/s13402-023-00808-7.

The Regulation of circRNA RNF13/miRNA-1224-5p Axis Promotes the Malignant Evolution in Acute Myeloid Leukemia.

Zhang R, Li Y, Wang H, Zhu K, Zhang G Biomed Res Int. 2020; 2020:5654380.

PMID: 33083473 PMC: 7557902. DOI: 10.1155/2020/5654380.

Overexpression of annexin A5 might guide the gemtuzumab ozogamicin treatment choice in patients with pediatric acute myeloid leukemia.

Zhang N, Zhang Y, Zhang P, Lou S, Chen Y, Li H Ther Adv Med Oncol. 2020; 12:1758835920927635.

PMID: 32636939 PMC: 7310896. DOI: 10.1177/1758835920927635.

References

Yang L, Perry C . Histamine dihydrochloride: in the management of acute myeloid leukaemia. Drugs. 2010; 71(1):109-22. DOI: 10.2165/11206410-000000000-00000. View

Burnett A, Hills R, Milligan D, Kjeldsen L, Kell J, Russell N . Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2010; 29(4):369-77. DOI: 10.1200/JCO.2010.31.4310. View

Speletas M, Ritis K, Bourikas G . Achievement and maintenance of complete remission in a patient with acute myelogenous leukemia after weekly administration of interleukin-2. Haematologica. 1996; 81(4):346-8. View

Hourigan C, McCarthy P, de Lima M . Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013; 20(2):154-63. PMC: 4205045. DOI: 10.1016/j.bbmt.2013.11.017. View

Pratcorona M, Brunet S, Nomdedeu J, Ribera J, Tormo M, Duarte R . Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood. 2013; 121(14):2734-8. DOI: 10.1182/blood-2012-06-431122. View

Stelljes M, Beelen D, Braess J, Sauerland M, Heinecke A, Berning B . Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial. Haematologica. 2011; 96(7):972-9. PMC: 3128215. DOI: 10.3324/haematol.2011.041004. View

Lowenberg B, Pabst T, Vellenga E, van Putten W, Schouten H, Graux C . Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011; 364(11):1027-36. DOI: 10.1056/NEJMoa1010222. View

Warlick E, Paulson K, Brazauskas R, Zhong X, Miller A, Camitta B . Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant. 2013; 20(2):202-8. PMC: 3924751. DOI: 10.1016/j.bbmt.2013.10.023. View

Sockel K, Bornhaeuser M, Mischak-Weissinger E, Trenschel R, Wermke M, Unzicker C . Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial. Haematologica. 2012; 97(9):e34-5. PMC: 3436225. DOI: 10.3324/haematol.2012.067629. View

10.

LEVI J, Wiernik P . A comparative clinical trial of 5-azacytidine and guanazole in previously treated adults with acute nonlymphocytic leukemia. Cancer. 1976; 38(1):36-41. DOI: 10.1002/1097-0142(197607)38:1<36::aid-cncr2820380107>3.0.co;2-m. View

11.

Burnett A, Goldstone A, Hills R, Milligan D, Prentice A, Yin J . Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. J Clin Oncol. 2013; 31(10):1293-301. DOI: 10.1200/JCO.2011.40.5977. View

12.

Stein A, ODonnell M, Slovak M, Snyder D, Nademanee A, Parker P . Interleukin-2 after autologous stem-cell transplantation for adult patients with acute myeloid leukemia in first complete remission. J Clin Oncol. 2003; 21(4):615-23. DOI: 10.1200/JCO.2003.12.125. View

13.

Peterson B, Bloomfield C . Prolonged maintained remissions of adult acute non-lymphocytic leukaemia. Lancet. 1977; 2(8030):158-60. DOI: 10.1016/s0140-6736(77)90178-7. View

14.

Hengeveld M, Suciu S, Karrasch M, Specchia G, Marie J, Muus P . Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization.... Ann Hematol. 2012; 91(6):825-35. PMC: 3345117. DOI: 10.1007/s00277-012-1436-z. View

15.

Chen Y, Borthakur G . Lenalidomide as a novel treatment of acute myeloid leukemia. Expert Opin Investig Drugs. 2013; 22(3):389-97. DOI: 10.1517/13543784.2013.758712. View

16.

Buchner T, Hiddemann W, Wormann B, Loffler H, Maschmeyer G, Hossfeld D . Longterm effects of prolonged maintenance and of very early intensification chemotherapy in AML: data from AMLCG. Leukemia. 1992; 6 Suppl 2:68-71. View

17.

Bloomfield C, Lawrence D, Byrd J, Carroll A, Pettenati M, Tantravahi R . Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998; 58(18):4173-9. View

18.

Kolitz J, George S, Benson Jr D, Maharry K, Marcucci G, Vij R . Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. Cancer. 2014; 120(7):1010-7. PMC: 4139069. DOI: 10.1002/cncr.28516. View

19.

Moore J, George S, Dodge R, Amrein P, Powell B, Kolitz J . Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood. 2004; 105(9):3420-7. PMC: 1895015. DOI: 10.1182/blood-2004-08-2977. View

20.

Fukushima T, Urasaki Y, Yamaguchi M, Ueda M, Morinaga K, Haba T . A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia. Anticancer Res. 2012; 32(2):643-7. View